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The blood–brain barrier (BBB) is a selective endothelial interface that controls trafficking between the bloodstream
and brain interstitial space. During development, the BBB arises as a result of complex multicellular interactions
between immature endothelial cells and neural progenitors, neurons, radial glia, and pericytes. As the brain
develops, astrocytes and pericytes further contribute to BBB induction and maintenance of the BBB phenotype.
Because BBB development, maintenance, and disease states are difficult and time-consuming to study in vivo,
researchers often utilize in vitro models for simplified analyses and higher throughput. The in vitro format also
provides a platform for screening brain-penetrating therapeutics. However, BBB models derived from adult tissue,
especially human sources, have been hampered by limited cell availability and model fidelity. Furthermore, BBB
endothelium is very difficult if not impossible to isolate from embryonic animal or human brain, restricting
capabilities to model BBB development in vitro. In an effort to address some of these shortcomings, advances in
stem cell research have recently been leveraged for improving our understanding of BBB development and
function. Stem cells, which are defined by their capacity to expand by self-renewal, can be coaxed to form various
somatic cell types and could in principle be very attractive for BBB modeling applications. In this review, we will
describe how neural progenitor cells (NPCs), the in vitro precursors to neurons, astrocytes, and oligodendrocytes,
can be used to study BBB induction. Next, we will detail how these same NPCs can be differentiated to more
mature populations of neurons and astrocytes and profile their use in co-culture modeling of the adult BBB. Finally,
we will describe our recent efforts in differentiating human pluripotent stem cells (hPSCs) to endothelial cells with
robust BBB characteristics and detail how these cells could ultimately be used to study BBB development and
maintenance, to model neurological disease, and to screen neuropharmaceuticals.
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Blood–brain barrier development and maintenance
In order to appreciate the potential impact for stem cell
modeling of the BBB, it is useful to briefly review the pro-
cesses of BBB formation and maintenance. Unlike other
tissues, central nervous system (CNS) vascularization is
exclusively driven by angiogenesis. In rodents, cerebral
blood vessels are formed around embryonic day 9 (E9) by
sprouting from the perineural vascular plexus (PNVP) [1],
a primitive vascular network surrounding the neural tube
(Figure 1). Under the influence of vascular endothelial
derived growth factor (VEGF), Angiopoietin-1, and sonic
hedgehog (Shh) secreted by the neuroepithelium lining* Correspondence: shusta@engr.wisc.edu
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distribution, and reproduction in any mediumthe subventricular zone [2], certain endothelial cells (ECs)
of the PNVP switch their phenotype to tip cells, a highly
invasive and migratory EC type that initiates blood vessel
sprouting into the neural tube. Differentiating brain endo-
thelial cells are anchored on a primitive basement mem-
brane (BM) formed by various extracellular matrix (ECM)
proteins including collagen IV, fibronectin, laminin-1 and
entactin/nidogen-1 [3-5]. Also, the rapid coverage of such
newly formed microvasculature by pericytes suggests that
they may be the first cell type of the neurovascular unit to
physically interact with endothelial cells [5]. In addition to
pericytes, neighboring undifferentiated neural progenitor
cells (NPCs), differentiating NPCs, and radial glia also ap-
pear to exercise an influence on the developmental BBB as
studies have suggested their ability to induce barrier prop-
erties in brain endothelial cells in vitro and in vivo [6-9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Schematic representation of the developmental and adult BBB. Embryonic blood vessels invade the neural tube by the migration
of the tip cell towards the neuroepithelium. Newly forming blood vessels actively recruit pericytes (PC) that ensure the stabilization of the new
structure and synthesize an embryonic basement membrane (BM). In parallel to cerebral angiogenesis, neural progenitor cells (NPCs) originating
from the neuroepithelium start to migrate towards the upper layers of the cerebral cortex using radial glia (RG) as a guidance structure. During
their migration, these NPCs begin differentiation into neuroblasts (NB) and maturing neurons (MN). In contrast to the developmental BBB, the
adult BBB constitutes a more elaborate structure. The cerebral vasculature shares a BM with PCs. The BM is more complex and is surrounded by
an external tunica, the glia limitans (GL). The BM and the GL are separated by a perivascular space. On the outer side of the GL, blood vessels are
highly invested by astrocyte end-feet processes (AC) and surrounded by neurons and microglial cells (MG). Neurons may directly and indirectly
interact with the cerebral vasculature.
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lature remains devoid of astrocytes as such cells only ap-
pear at the end of gestation and early postnatal stages
[10,11]. While the nature of the molecular signals
imparted on the brain endothelial cells by the neighboring
cells of the developing neurovascular unit remains unclear,
recent studies have highlighted the importance of Wnt
signaling (through the secretion of Wnt7a/Wnt7b, likely
by NPCs), GPR124 and Shh [6,12-18]. During embryonic
development, functional barrier properties are acquired as
demonstrated by a continuous increase in tight junction
(TJ) organization [19,20]. This process results in barrier
maturation, marked by an increase in transendothelial
electrical resistance (TEER) from < 500 Ωxcm2 to ~1500
Ωxcm2 [21] with a concomitant decrease in permeability
to water-soluble compounds such as mannitol, potassium
or urea [22,23].
Although barrier properties are certainly induced dur-
ing embryonic development, they remain attenuated
when compared to the adult BBB. An examination of
the multicellular composite that helps maintain the adult
BBB reveals that pericytes remain in contact with ECs,
sharing a more elaborate BM formed by different ECM
components including agrin, laminin, perlecan andSPARC/osteonectin (Figure 1). The developmental
brain parenchyma is replaced by a densely populated
neuropil formed by neurons and glial cells supported by
a chondroitin-sulfate proteoglycan-rich matrix [24]. Un-
like the early stages of embryonic BBB development
when astrocytes are absent, astrocytes play important
roles in BBB maturation and maintenance. As a result of
this adult brain microenvironment and in contrast to the
developmental BBB, the adult BBB boasts an elevated
TEER, measured at average values between 1000–2000
Ωxcm2 (and maximum values up to 6000 Ωxcm2) and a
correspondingly lower passive permeability to molecular
tracers [21,25,26]. These mature brain endothelial cells
also express a broad array of large and small molecule
transport systems including nutrient influx transporters
and efflux transporters such as p-glycoprotein (p-gp),
multi-drug resistance-associated proteins (MRP), and
breast cancer resistance protein (BCRP) (for a review,
see [27]). While the mechanisms driving the further in-
duction and maintenance of the adult BBB are unre-
solved, several growth factors and signaling molecules
such as angiopoietin-1 [28], cyclic adenosine monopho-
sphate [29], basic fibroblast growth factor [30], glial-
derived neurotrophic factor [31], glucocorticoids [32,33],
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[34], Shh [14], transforming growth factor β [35] and
Wnt3a [13] have been shown to have effects on the BBB
phenotype in vitro. Importantly, the BBB phenotype is
dictated by the local microenvironment and is not in-
trinsic to brain endothelial cells themselves [36]; and
thus, primary brain microvascular endothelial cells
(BMECs) rapidly lose their barrier features in vitro.
When modeling the BBB, as discussed in the upcoming
section, it is important to take into account the micro-
environment that needs to be recreated with the embry-
onic and adult neurovascular units comprising very
different cellular and molecular architectures.
In vitro modeling of the BBB
Modeling the BBB in vitro can facilitate a variety of stud-
ies that are not amenable to in vivo investigation. For ex-
ample, in vivo experiments, such as those performed
with knockout animals, are largely restricted to evaluat-
ing basic phenotype alterations, resulting in a limited
understanding of underlying molecular and cellular
mechanisms that may govern a physiological process or
BBB dysfunction in a disease state. Also, while detailed
drug delivery evaluation can only be performed in vivo,
mining through large combinatorial libraries of small
molecule or protein libraries is not compatible with
in vivo approaches. Finally, in vivo investigation of the
BBB is mostly performed in animals, with investigation
of the human BBB being limited to non-invasive meth-
ods such as magnetic resonance imaging techniques.
Because of the significant challenges presented by
in vivo studies, in vitro models have been under deve-
lopment and utilized in countless scientific studies
(Figure 2). One longstanding approach consists of isolat-
ing and culturing primary BMECs. Given the aforemen-
tioned complex intercellular interplay that defines the
embryonic and adult neurovascular unit, one can im-
agine that removal of BMECs from their brain micro-
environment and growth in culture can lead to loss of
BBB phenotype. To date, there has been very limited
success in coaxing embryonic BMECs to grow ex vivo
[37]. On the other hand, adult BMECs have been cul-
tured successfully by many laboratories, but they rapidly
lose their in vivo phenotype resulting in comparatively
poor TEER (100–200 Ωxcm2), high paracellular perme-
ability (~100x higher than the in vivo situation) and
decreased transporter expression compared to the same
cells in vivo [38-40]. In addition, given that brain
vasculature comprises only 0.1% of the brain by volume,
such techniques require a significant amount of brain
material to achieve a reasonable yield of BMECs, limit-
ing high throughput applications. A seemingly inviting,
scalable alternative is the use of immortalized brain
endothelial cell lines. Examples of widely used brainendothelial cell lines described in the literature include
the immortalized hCMEC/D3 human cell line [41], the
rat RBE4 cell line [42] and the mouse bEnd.3 cell line
[43]. The main advantage of such cell lines is the expan-
sion capacity derived from their immortalized status.
However, while these cell lines maintain many aspects of
their primary BMEC counterparts and represent very
useful tools for certain applications, they lack significant
barrier function [44,45].
In order to improve primary BMEC properties, various
approaches to re-introduce aspects of the in vivo micro-
environment have been reported. Astrocyte co-culture
systems are the most widely used [46,47]. In this model,
BMECs are cultivated, usually in a non-contact format,
with primary astrocytes isolated from newborn rodents
(Figure 2). Addition of astrocytes can improve barrier
function as measured by increases in TEER and
decreases in passive permeability [47-50]. Following the
isolation and characterization of adult brain pericytes by
Dore-Duffy and colleagues [51], several studies high-
lighted the ability of primary pericyte co-cultures to im-
prove barrier function. Finally, by comparison, the
impact of neurons on barrier function in vitro appears
lessened compared with astrocytes and pericytes [52-55].
Co-culture with each of these cell types alone has been
reported to increase TEER [47,56] and decrease para-
cellular permeability [47,52,56]. Such improved barrier
properties involved enhancement of TJ complexes as
observed by increased protein levels as well as an
enhanced localization [46,49,53,55,57,58]. In addition to
improved barrier phenotype, several studies also
reported an enhanced efflux transporter activity, in par-
ticular that mediated by p-gp [56,59]. Comparatively,
astrocytes co-cultures appear to have better induction
on barrier properties and TJ complexes formation than
pericytes as noted by different studies [58,60,61]. How-
ever such studies also noted a partial additive effect
in vitro when BMECs were co-cultured simultaneously
with astrocytes and pericytes [60,61] (Figure 2), suggest-
ing that these cell types may use common signaling
pathways or act synergistically to induce barrier proper-
ties in BMECs, while also inducing some cell-specific
signaling pathways. In addition to conventional 2-
dimensional co-cultures models, different in vitro BBB
models have been developed in the last decade using
natural (collagen, hydrogel) or synthetic materials (poly-
propylene) to obtain a 3-dimensional scaffold structure
[62-65]. These models demonstrate the effects of two-
dimensional co-culture, three-dimensional co-culture, or
continuous laminar shear stress on BMEC morphogen-
esis and barrier-genesis.
Although the BBB properties of such multicellular co-
culture models have improved as a result of the syner-
gistic combination of the various cell types of the
Figure 2 Schematic representation of the various BBB in vitro models. Cells are isolated from whole brain tissue (non-human origin) or from
biopsied tissue samples (human origin). From these sources, primary cultures of BMECs, astrocytes, pericytes and neurons can be achieved. In the
case of BMECs, immortalized cells lines have been established from both rodent (bEnd.3, RBE4) and human (hCMEC/D3) cells. Cells can be
cultivated in either a BMEC monoculture or in a co-culture model including any combination of astrocytes, pericytes and neurons. Co-cultures
can be established in a non-contact manner or in a contact manner by seeding a co-cultured cell on the other side of the filter.
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ate the in vivo BBB phenotype. In addition, implementa-
tion of such models is limited by two factors: workflow
and scalability. Neurons (embryonic), astrocytes (postna-
tal), pericytes (adult), and BMECs (adult) are isolated
from animals of various ages, resulting in a laborious
process of many singular primary cell isolations, and
yields from several of these isolations, particularly of
BMECs, are quite low. Finally, although cellular cross-
talk can be observed between BBB cells from different
species [47,66], mixed species co-cultures might remain
suboptimal compared to syngeneic co-cultures. Because
such syngeneic co-cultures remain limited to rodent
BBB models, it would be useful to have a new approach
to obtain an all-human in vitro BBB model.
Stem cells sources for BBB modeling
A stem cell-based paradigm has the potential to offer
substantial advantages for BBB modeling because of the
current challenges with multicellular complexity, scal-
ability, human sourcing, and the inability to culture pri-
mary BMECs at different developmental time points,
particularly early in embryonic development. As a brief
background, a stem cell is generally defined by its cap-
acity for extensive self-renewal and ability to generate
terminal progeny. In broad terms, stem cells give rise to
all cells in the human body throughout various stages ofdevelopment and then often reside in specific locations,
or niches, during adulthood, such as in the subventricu-
lar zone and the hippocampal dentate gyrus of the brain
[67-69] and the hematopoietic stem cells in the bone
marrow [70]. Various populations of stem cells can be
isolated during development and from adult tissues, and
the properties they possess are dependent on the timing
and location of the isolation. Embryonic stem cells
(ESCs), which are derived from the inner mass of
blastocyst-stage embryos, are termed pluripotent be-
cause they can form somatic cells from all three primi-
tive germ layers (ectoderm, endoderm, and mesoderm)
[71-73]. Stem cell populations with more restricted fate
potential, including most adult stem cells, are termed
multipotent. For instance, neural progenitor cells (NPCs)
isolated from the embryonic CNS can differentiate into
neurons, astrocytes, and oligodendrocytes [74,75]. Som-
atic cells can also be reprogrammed to a pluripotent
state (induced pluripotent stem cells; iPSCs) or multipo-
tent state (e.g. induced neural stem cells) via forced ex-
pression of various transcription factors regulating
pluripotency [76-81]. These various types of stem cells,
especially human ESCs (hESCs) and human iPSCs
(hiPSCs), have enormous potential for the study of
human development and disease. For instance, hPSCs
have been differentiated into diverse cell types such as
cardiomyocytes [82], beta-pancreatic cells [83], neurons
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structures such as the optic cup [86], typically by direc-
ted manipulation of intracellular and extracellular signal-
ing pathways via protein or small molecule treatments,
intercellular interactions, mechanotransduction, or
matrix-mediated cues [87] (Figure 3). These differenti-
ation protocols allow access to cell populations, includ-
ing transient developmental progenitors and terminally
differentiated cells that would otherwise be unattainable
from human tissue. hiPSCs can also be used to capture
and study the phenotype of various genetic diseases [88]
such as spinal muscular atrophy [89], Alzheimer’s dis-
ease [90], familial dysautonomia [91], and Rett syndrome
[92] by isolating cells from a patient harboring the gen-
etic disease, creating an iPSC line, and differentiating
that line to the cell type(s) affected by the disease. hPSCs
also offer significant utility for screening prospective
therapeutics. Compounds screened in animals or against
cell lines often fail in clinical trials due to toxicity or a
lack of efficacy [93], which highlights the need for
improved model systems for drug screening. Human
PSCs have thus far gained traction for testing drugs for
heart toxicity using hPSC-derived cardiomyocytes
[94,95] and may be useful for other organs if the relevant
hPSC-derived cell types adequately represent their
in vivo counterparts.
The aforementioned properties of stem cells make
them attractive candidates for modeling the BBB. Unlike
primary cells, stem cells can be propagated extensively
in vitro and because they can be derived from a clonal
source, their progeny have a homogeneous genetic pro-
file. Stem cells can also provide intermediate populations
in development whereas mature cells isolated from adult
tissue cannot. To apply stem cells to BBB modeling
applications, the appropriate stem cell population mustFigure 3 Methods for differentiating hPSCs. hPSCs can be differentiated
conditions. Soluble cues, including growth factors and small molecules, can
Extracellular matrix composition can also influence cell fate. Autocrine, para
substantially affect differentiation outcomes. Mechanical forces can also bebe selected. Namely, modeling BBB development
requires cells with an embryonic phenotype, whereas
modeling BBB maintenance and constructing a model
for drug screening would require cells with a mature
adult phenotype. To this end, we have utilized multiple
stem cell sources in our laboratory for various BBB
applications over the last several years. We first utilized
NPCs to model aspects of BBB development and
demonstrated that embryonic NPCs in the early stages
of differentiation contribute to BBB properties in vitro
[9]. We next utilized NPC-derived neurons and astro-
cytes having a more mature phenotype for modeling the
adult BBB [66]. Finally, we have recently described a
process to generate BMECs from hPSCs and monitor
human BBB development in vitro [96]. Upon matur-
ation, these BMECs may also be useful for drug screen-
ing applications. In this review, we will describe these
efforts in detail, as well as outline the potential uses and
concerns of each cell source to motivate future work.
Stem cell modeling of the BBB
Stem cell modeling of BBB development
As discussed, cell types other than astrocytes are likely
responsible for the initial induction of BBB properties
during embryonic development. To address this issue,
our research group used embryonic NPCs along with
primary BMECs as an in vitro model of the developmen-
tal BBB (Figure 4a) [9]. The purpose of this study was to
isolate a population of rat cortical NPCs from embryonic
day 14 (E14), corresponding to the timeframe when the
BBB phenotype is induced in vivo but prior to astrocyte
formation, and determine their capability for inducing
BBB properties in cultured adult rat BMECs. The initial
results from this study indicated that NPCs maintained
in their undifferentiated state could not induce BBBto many different somatic cell types by manipulating a variety of
activate or inhibit signaling pathways to help direct cell fate.
crine, or juxtacrine signaling between neighboring cells can
applied to guide hPSC differentiation.
Figure 4 Schematic representation of BMEC-NPC co-culture schemes. a) NPCs were first utilized to examine non-contact interactions with
rat BMECs. b) NPCs of rat and human origin were pre-differentiated to mixtures of neurons, astrocytes, and oligodendrocytes and co-cultured
with rat BMECs. Human NPCs differentiated for 9 days yield progeny such as βIII tubulin+ neurons (left panel; red) and GFAP+ astrocytes (right
panel; red) with extensive nestin expression (green). Scale bars indicate 50 μm.
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the early stages of differentiation were co-cultured with
BMECs, the BMECs exhibit an increase in passive bar-
rier properties as measured by elevated TEER and
decreased permeability to the small molecule tracer so-
dium fluorescein. At an ultrastructural level, BMECs co-
cultured with differentiating NPCs possessed a higher
percentage of smooth and continuous tight junctions as
determined by monitoring the localization of proteins
such as claudin-5, occludin, and ZO-1. Analysis of the
NPC-derived progeny revealed that differentiation in the
presence of BMECs resulted in significantly more cells
expressing nestin (a marker of immature neural progeni-
tors) but fewer cells undergoing neuronal differentiation
as measured by βIII tubulin expression, a similar finding
to that shown previously using a mouse brain endothe-
lial cell line in co-culture with NPC-derived cells [97].
Interestingly, if instead NPCs were differentiated for
24 hours in the absence of BMECs prior to co-culture,
the mixture contained more βIII tubulin+ neurons and
fewer nestin-expressing precursors, but the co-cultures
were unable to substantially induce elevated BMEC
TEER. Taken together, these results indicated that NPCs
in their early stages of differentiation, likely in the
nestin-expressing state, have the potential to induce BBB
properties in BMECs, and do so in a manner distinct in
timing and duration from postnatal astrocytes. Other
researchers have confirmed the influence of NPCs on
BBB character in vitro [98], and several studies have
since linked BBB induction to Wnts supplied by thedeveloping neural tube in vivo, identifying a potential
link between the in vitro and in vivo effects of NPCs
[6,8].
A limitation of the aforementioned developmental
BBB model was the use of adult BMECs as opposed to
embryonic BMECs. Thus, we next attempted to employ
hPSCs to generate a more representative model of the
developmental BBB in which brain endothelial inductive
cues could be identified and systematically analyzed.
While endothelial cells have previously been differentiated
from hPSCs, they had not yet been shown to possess
organ-specific phenotypes or gene expression signatures
[99-101]. However, given the embryonic brain microenvir-
onment comprising primitive endothelial cells and differ-
entiating NPCs and our findings that differentiating NPCs
could induce BBB properties, we hypothesized that co-
differentiating neural cells could impart a BBB phenotype
on hPSC-derived endothelium (Figure 5) [96]. To this end,
we identified differentiation and culture conditions where
hPSCs generate a co-differentiating mixture of primitive
endothelium and NPCs. In this approach, a population of
PECAM-1+ cells lacking tight junctions and mature endo-
thelial cell markers such as von Willebrand Factor (vWF)
and VE-cadherin was expanded within a mixed neural
population predominantly comprised of nestin+/βIII tubu-
lin- progenitors and nestin+/βIII tubulin+ immature neu-
rons. These neural populations expressed WNT7A and
WNT7B, which are expressed by NPCs in vivo, and con-
tribute to BBB development [6,8]. As the neural popula-
tion matured into mainly nestin+/βIII tubulin+ and
Figure 5 Progress towards an all-human stem cell-derived in vitro BBB model. hPSCs can be co-differentiated as a mixture of neural cells and
BMECs, and the BMECs can be subcultured as a pure monolayer expressing typical endothelial and BBB markers such as PECAM-1, VE-cadherin,
occludin, and claudin-5. Several options are theoretically possible for creating an all-human BBB model with these hPSC-derived BMECs. Human NPCs
could potentially be used to create a BMEC/NPC co-culture model as a representative in vitro model of the developing human BBB. Alternatively,
human NPCs could be pre-differentiated into mixed neuron/astrocyte cultures to model the adult BBB. Ideally, future applications will involve using
hPSCs to obtain all the different cells forming the neurovascular unit. This approach could also facilitate the use of hiPSCs derived from both healthy
and diseased patients to obtain a physiological or diseased model of the human BBB in vitro. Scale bar indicates 25 μm.
Lippmann et al. Fluids and Barriers of the CNS 2013, 10:2 Page 7 of 14
http://www.fluidsbarrierscns.com/content/10/1/2nestin-/βIII tubulin+ neurons, the endothelial cells began
to express hallmark biomarkers of the BBB including tight
junction proteins (e.g. claudin-5, occludin), the glucose
transporter Glut-1, and the efflux transporter p-gp/MDR1
(termed hPSC-derived BMECs). Acquisition of these prop-
erties in the endothelium occurred in concert with trans-
location of β-catenin to the nucleus, suggesting an onset
of Wnt-mediated signaling similar to in vivo studies [6,8].
Interestingly, glial fibrillary acidic protein+ (GFAP+) astro-
cytes and α-SMA+ pericytes/smooth muscle cells were
detected at less than 1% of the total population and thus
were not likely major contributors to the onset of BBB
properties. Selective expansion in an endothelial cell
growth medium based on formulations normally used for
primary BMEC culture further enhanced the BBB pheno-
type in terms of Glut-1 expression level, while treatment
with soluble inhibitors of Wnt signaling partially disrupted
the acquisition of the BBB phenotype, indicating the po-
tential contribution of neural cell-derived Wnts to this
in vitro differentiation process. Interestingly, inhibition of
Wnt signaling did not disrupt tight junction formation,
which agrees with in vivo observations that endothelial-
specific β-catenin knockout mice exhibit CNS hemorrhage
but still possess BMECs expressing occludin and claudin-5
[6], and indicates that Wnt/β-catenin signaling is not the
exclusive pathway regulating hPSC-derived BMEC forma-
tion [15-17]. Overall, these results demonstrate thatendothelial cells having BBB properties can be obtained
from primitive endothelium derived from hPSCs in a
process that may mimic certain aspects of in vivo
development.
These studies summarize the current use of stem cell
sources for modeling BBB development. Stem cells offer
many advantages over primary cells for studying devel-
opment in vitro. For one, cellular yields are inconse-
quential when using stem cells due to the ability to scale
undifferentiated cell populations, whereas primary em-
bryonic sources of endothelial cells and particularly
BMECs are nearly impossible to obtain in significant
amounts. Another benefit is the ability to use human
cells without needing access to scarce primary human
tissue resources. In addition, while we and others have
routinely used primary adult BMECs or cell lines to in-
vestigate the BBB induction process, this practice is
largely flawed because in these cases one must combat
an in vitro de-differentiation artifact, which does not ne-
cessarily correlate to induction and maintenance
through a developmental pathway as one would expect
with stem cell-based methods. This reasoning does not
imply that all molecular and cellular studies using adult
BMECs to model BBB induction are without merit; but
instead, emphasizes that care must be exercised to inter-
pret results obtained by the model in the appropriate
context. Lastly, hPSC-derived BMECs could potentially
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pathways relevant to BBB induction, as demonstrated by
the observation that Wnt/β-catenin signaling affects ac-
quisition of BBB properties. However, similar to the cau-
tions described above for primary or cell line systems,
care must be taken in the interpretation of such results
and assumptions of in vivo relevance. For instance,
in vitro differentiation may not fully recapitulate in vivo
development if important molecular cues are absent or
introduced at a time point where the hPSC-derived
BMECs are not receptive to the cues. In our hPSC study,
IMR90-4 and DF19-9-11T hiPSCs could be differen-
tiated to pure populations of BMECs, but H9 hESCs
generated a mixture of BMECs and non-BBB endothe-
lium [96], presumably due to the reasons listed above.
Similarly, other cues that are not typically present during
in vivo BBB development could potentially induce BBB
properties through a pathway distinct from that followed
in normal development. Therefore, it would be advisable
to use stem cell-derived BBB models as a complement,
but not a replacement, for existing in vivo approaches
such as transgenic animal models. Researchers are also
becoming increasingly aware that heterogeneity in the
brain is encoded during embryonic development [102-104]
and the signals that govern this development may also con-
tribute directly to patterns of brain vascularization and
acquisition of BBB properties [105]. Therefore, NPCs iso-
lated as bulk cortical populations and hPSCs differentiated
to heterogeneous neural cells are unlikely to capture this
diversity. Recent evidence has also suggested BBB hetero-
geneity in adult brain vessels at potentially single cell levels
[106]. As such, future studies to determine the extent of
hPSC-derived BMEC heterogeneity may also be an impor-
tant consideration.
Stem cell modeling of BBB maintenance and regulation
While modeling BBB development requires embryonic
neural cells and immature BMECs, modeling adult BBB
maintenance requires mature BMECs along with co-
cultured cells of the adult neurovascular unit such as
pericytes, astrocytes, and neurons (Figure 1). Unfortu-
nately, adult BMECs and co-cultured cells are most
often isolated from non-human sources, are generally
acquired in low yield, are heterogeneous between isolations,
and de-differentiate upon extended culture [107-109]. Stem
cells could therefore also be an attractive alternative for
adult BBB modeling.
To date, we have investigated using stem cells to re-
place primary neurons and astrocytes in in vitro
co-culture models [66]. In this study, rat NPCs were dif-
ferentiated under several different conditions to produce
mixtures of neurons, astrocytes, oligodendrocytes, and
proliferating neural progenitors (Figure 4b). The critical
phenotype evaluated in this case was the capability ofNPC-derived cell mixtures to induce TEER in cultured
adult rat BMECs. By tuning differentiation time and
medium composition, NPCs were differentiated to a
mixture consisting predominantly of GFAP+/nestin+
astrocytes and nestin+/GFAP-/βIII tubulin- progeni-
tors that could effectively induce TEER compared to
mixtures containing βIII tubulin+ neurons as the
major population. Furthermore, NPCs differentiated for
extended periods of time (12 days vs. 6 days) were more
effective for TEER induction. With longer differentiation
time, astrocytes acquired multiple extended processes
indicative of physical maturation, which may contribute
to their regulation of BBB phenotype. NPCs also exhibit
a stable transcriptome after extended proliferation in the
undifferentiated state [110], and accordingly, the ability
of differentiated NPCs to upregulate TEER was un-
changed between freshly isolated and extensively pas-
saged NPCs, indicating the NPCs could be expanded to
large yields without adverse effects on BBB induction. In
addition to TEER, differentiated NPCs also regulated
p-gp activity, tight junction fidelity in terms of continu-
ous intercellular localization, and expression of various
genes in a manner similar to primary astrocytes. Finally,
these general strategies were adapted for human NPCs,
and mixtures of astrocytes and neurons derived from
human NPCs could similarly upregulate TEER in cul-
tured rat BMECs, indicating NPCs could also be useful
for human BBB modeling applications.
To further facilitate studies of human BBB mainten-
ance and regulation, we developed a protocol for purify-
ing the immature hPSC-derived BMECs described
earlier, and used these cells to model the mature BBB
(Figure 5) [96]. Facile purification of the hPSC-derived
BMECs by passaging the mixed differentiated cultures,
consisting of endothelial and neural cell types, onto col-
lagen IV/fibronectin matrix yielded purified endothelial
cell monolayers that when co-cultured with primary rat
astrocytes possessed substantial barrier properties (max-
imum TEER achieved = 1450 Ωxcm2; average TEER over
30 independent differentiation and purification experi-
ments = 860 ± 260 Ωxcm2), far exceeding reported values
for primary cell and cell line-based human BBB models
[41,48]. In addition, during the purification process the
cells matured from a vascular perspective gaining VE-
cadherin and vWF expression, and could uptake acety-
lated low-density lipoprotein and form vascular tubes
upon VEGF stimulation. These hPSC-derived BMECs
also expressed transcripts encoding a number of recep-
tors and transporters found at the BBB in vivo, including
nutrient receptors, amino acid and peptide transporters,
and efflux transporters. Moreover, the efflux transporters
were shown to possess functionally polarized activity
similar to other primary models [96]. While the hPSC-
derived model possesses favorable barrier characteristics
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questions need to be addressed to determine if hPSC-
derived BMECs truly represents the “adult” BBB pheno-
type. For instance, despite elevated TEER (800–1000 Ω
xcm2), the hPSC-derived BMECs still possess inferior
barrier properties compared to the in vivo BBB (mea-
sured up to ~6000 Ωxcm2 in rats [21]). Along these
lines, hPSC-derived BMECs do not encounter pericytes
during the co-differentiation process [96], whereas peri-
cytes contribute substantially to BBB development
in vivo [7,111]. As such, optimization of hPSC-derived
BMEC differentiation through discovery of other import-
ant BBB inductive factors and employment of additional
co-culture schemes will likely be necessary to more fully
reconstitute BBB properties. In addition, as has recently
been performed for primary cultured BMECs [38,112]
and the hCMEC/D3 line [113-115], transcriptome,
proteome, and functionality tests will be required to de-
termine how closely these cells resemble their in vivo
counterparts and to determine which types of BBB stud-
ies are best supported by the hPSC-derived BBB model.
To enhance BBB properties, components from each of
the aforementioned stem cell modeling strategies
could be combined to form a more accurate in vitro
model. Human NPC-derived astrocytes and neurons
(Figure 4b), for instance, could be utilized for co-culture
with hPSC-derived BMECs. hPSCs have also been differ-
entiated to astrocytes that exhibit some broad positional
identity (e.g. dorsal vs. ventral and forebrain vs. hind-
brain) [116,117], and these cells could be used to probe
potential differences in region-specific BBB induction
and maintenance. Along these lines, certain neurogenic
regions of the adult brain may rely on interactions be-
tween the resident NPC population and brain vascula-
ture to maintain NPC stemness and regulate the local
barrier properties of the endothelium [118]. Thus, a
combination of hPSC-derived BMECs and hPSC-derived
NPCs [119] could potentially be used to model these
complex interactions. In addition to brain cells, vascular
cells with putative pericyte identity have also been differ-
entiated from hPSCs [120,121]. Overall, hPSCs consti-
tute a single cell source from which all components of
an adult BBB model could in principle be obtained
(Figure 5), pending advances in hPSC differentiation
procedures to more appropriately capture the phenotype
of each mature cell in the neurovascular unit. However,
extensive characterization of each type of cell would be
required to qualify these cell sources for BBB modeling.
One area where hPSCs have a clear advantage over
primary cells and cell lines is in the modeling of diseases
having a genetic component. Whereas primary diseased
brain tissue is extremely heterogeneous and difficult to
obtain from humans, hiPSC lines can be created directly
from patients and then differentiated to the cell types ofinterest in high yield (Figure 5). Therefore, BBB models
constructed from hiPSC-derived progeny may have fu-
ture utility for understanding the genetic contributions
of components of the neurovascular unit to complex
CNS diseases. For instance, a recent study has identified
the mechanism by which an isoform of apolipoprotein E
(ApoE) contributes to neurodegeneration in Alzheimer’s
disease and demonstrated that vascular defects precede
the neurodegenerative disease phenotype [122]. There-
fore, hiPSCs could be generated from Alzheimer’s
patients carrying familial mutations that promote the
disease phenotype [90], and these hiPSCs could be dif-
ferentiated to both neurons and BMECs to study the
effects of ApoE isoforms on disease progression within
the neurovascular unit in vitro using human cells. In
general, as genetic, epigenetic, and environmental causes
of other neurological diseases become better understood,
hiPSCs could be used to capture the dynamics of disease
progression and cell-cell interactions in vitro.
Stem cell models for drug screening applications
As previously discussed, a major motivation for design-
ing an in vitro BBB model is the capability to assess drug
delivery potential of candidate therapeutics. In vitro
models using BMECs of non-human origin are most
widely used for drug screening [123-125]. Moreover, the
hCMEC/D3 line constitutes the only human brain endo-
thelial cell line widely available for larger scale screening
studies. Although these and other immortalized human
cell lines may have some potential for assessing drug
substrate potential for the various efflux transporters,
their usage for drug screening applications remains sub-
optimal due to low TEER values and relatively high basal
permeability [41].
The use of purified hPSC-derived human BMECs may
represent an alternative cell source for human BBB drug
screening [96]. As mentioned previously, while hPSC-
derived BMEC monocultures have reasonable baseline
TEER values (~250 Ωxcm2), they can achieve up to
1450 Ωxcm2 after medium and astrocyte co-culture
optimization. This model demonstrated lower perme-
ability to sucrose (Pe = 3.4 × 10
-5 cm/min) than those
values published on hCMEC/D3 monolayers (1.65 × 10-3
cm/min) [41] or bovine BMEC/astrocyte co-cultures
(0.75 × 10-3 cm/min) [123]. In addition to low sucrose
permeability, hPSC-derived BMECs co-cultures exhib-
ited a 40-fold range in permeability between diazepam
(BBB permeable) and sucrose (BBB impermeable) com-
pared with the 10-fold and 20-fold ranges reported for
hCMEC/D3 and bovine BMECs, respectively [41,123]. In
addition, a small cohort of molecules, including sub-
strates of influx and efflux transport, was analyzed for
permeability across the hPSC-derived in vitro BBB
model. The resultant permeability values correlated well
Lippmann et al. Fluids and Barriers of the CNS 2013, 10:2 Page 10 of 14
http://www.fluidsbarrierscns.com/content/10/1/2with in vivo uptake measured by in situ perfusion in
rodents. Another important standard for an in vitro BBB
model suitable for drug screening is the expression and
polarized activity of efflux transporters. Efflux transpor-
ters constitute a major challenge for drugs that may
present a low permeability despite having the desirable
size and lipophilic properties. Three members of the
ABC transporters that mediate much of the efflux activ-
ity at the BBB are p-gp (MDR1/ABCB1), MRPs (ABCCs)
and BCRP (ABCG2). hPSC-derived BMECs were found
to express p-gp, MRP-1, MRP-2, MRP-4, and BCRP
transcripts, and p-gp protein expression was validated
using immunocytochemistry [96]. Functional activity of
these transporters was confirmed using Rhodamine 123
and doxorubicin as substrates in both accumulation and
permeability assays. We noted a 2.3-fold increase in
trans-BBB transport for the p-gp substrate, Rhodamine
123, following p-gp inhibition by cyclosporin A (CsA).
Similar efflux inhibition results were noted with the
pan-substrate doxorubicin following inhibition with
CsA, Ko143 (BCRP inhibitor), or MK571 (pan-MRP in-
hibitor). The hCMEC/D3 cell line yields comparable efflux
inhibition values [126], but a larger, 3-fold change in
brain uptake of Rhodamine 123 is observed in rodents
upon p-gp inhibition [127]. Activity of these transporters
was also implicit by relative permeability measurements,
where colchicine, vincristine, and prazosin (substrates
recognized by various ABC transporters) exhibited lower
apical-to-basolateral permeability than their relative lipo-
philicity would suggest.
In addition to drug permeability screening and efflux
transporter assessment, hPSC-derived BMECs could
serve as a useful tool for evaluation of solute carriers,
receptors involved in receptor-mediated endocytosis and
transcytosis processes, or screening for BBB targeting
reagents. For example, the hPSC-derived BMECs express
transcripts encoding several solute carriers recognized as
enriched at the BBB such as Glut-1 (SLC2A1), large neu-
tral amino acid transporter-1 (SLC7A5), monocarboxy-
late transporter-1 (SLC16A1) and system N amino acid
transporter-5 (SLC38A5) [96]. Furthermore, the hPSC-
derived model appeared devoid of Oatp14 (SLCO1C1)
transcript, an organic anion transporter that is highly
expressed in rodents, but not humans [128,129], suggest-
ing at least a limited level of species restricted expres-
sion. We also reported transcript expression for several
receptors involved in receptor-mediated transport such
as insulin receptor, leptin receptor, and transferrin
receptor.
Ultimately, more extensive work will be necessary to
determine the full utility of hPSC-derived BMECs for
drug screens. For example, seven compounds were
tested in the original hPSC-derived BMEC model as a
proof of concept study, but this amount is by no meansexhaustive enough to determine its true predictive
power. Therefore, it would be advisable to test a larger
compound library. In addition, various transporters were
assayed at the transcript level and some at the protein
and functional levels. However, similar to other in vitro
models built on primary or cell line-based BMECs, it is
unlikely that hPSC-derived BMECs will ever fully mimic
the transcriptome and proteome of the in vivo BBB.
Thus, comparative analyses using techniques such as
quantitative mass spectrometry and microarray or RNA-
seq would be useful to determine both advantages and
shortcomings of these cells. Such data would also likely
yield molecular targets and pathways that need to be
modulated to achieve a screening platform more repre-
sentative of the in vivo BBB.
Finally, the choice of hPSC line may affect the predict-
ive nature of the resultant BMEC population. Line-to-
line variability in differentiation efficiency is not uncom-
mon when using hESCs or hiPSCs [130,131], and in our
experience, while each of the lines produced cells that
expressed BMEC markers in the mixed differentiating
cultures, the functional properties of the purified BMEC
population varied. It is interesting to note that different
hiPSC reprogramming methods and donor fibroblast
sources yielded purified BMECs having barrier pheno-
types. For example, IMR90-4-derived hiPSCs were re-
programmed from fetal lung fibroblasts using retroviral
transduction and DF19-9-11T hiPSCs were repro-
grammed from foreskin fibroblasts by non-integrating
episomal vectors. In contrast, the DF6-9-9T line, which
was derived in the same study as the DF19-9-11T line,
did not produce cells that generated a significant barrier
phenotype following the identical differentiation proto-
col. Furthermore, the H9 hESC line generated a mixture
of BMECs and non-BBB endothelium with this protocol.
While we have not yet explored the possibility, it may
also be possible that BMEC properties could be affected
by the type of reprogrammed somatic cell (i.e. repro-
grammed fibroblasts vs. neurons vs. endothelial cells,
etc.) or the individual donor as some studies have shown
that hiPSCs or cells differentiated from hiPSCs retain an
epigenetic memory of their cell type of origin [132-134]
or donor [135] following reprogramming. Overall, the
results from the initial hPSC study indicate the BMEC
differentiation protocol may have to be optimized and
validated for individual lines. Although methodological
enhancements are sure to improve the line-to-line
consistency in BMEC production, we would currently
recommend using the IMR90-4 hiPSC line as this line
has been the most extensively validated in our hands.
Importantly, once a line is validated, it is a highly scal-
able source of BMECs: by simply expanding cells in the
undifferentiated hPSC stage, one can generate enough
hPSC-derived BMECs for tens of thousands of Transwell
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are highly encouraged by the properties of this first
generation hPSC-derived BBB model, including its
phenotype, yield, and scalability, more extensive
characterization is warranted to test its utility for pre-
dictive drug screening applications.
Conclusions
Stem cells have proven useful over the last decade for
modeling various developmental and disease processes
in humans. They have also provided access to unlimited
quantities of differentiated human cells that are other-
wise difficult or impossible to acquire. Based on the
properties of hPSC-derived BMECs, and the lack of
existing human BMEC sources, a stem cell model of the
BBB could have significant impact on studies of BBB de-
velopment and maintenance as well as for drug screen-
ing applications. The hPSC-derived BMECs could also
be employed in BBB model formats that better mimic
the physiological microenvironment, such as in matri-
ces that enable the assembly of three-dimensional
vascular structures [62] or systems that incorporate
fluid flow [136]. Such improvements may further in-
crease the relevance of mechanistic studies of the
neurovascular unit or improve the predictive power
of drug screens.
Looking beyond the traditional uses for BBB models,
the capability to generate hiPSCs from patient-derived
materials offers an unexplored niche for stem-cell
derived BBB modeling. For instance, skin cells could be
biopsied from patients and control groups, repro-
grammed to pluripotent stem cells using any number of
hiPSC derivation techniques, and differentiated to pro-
vide an isogenic supply of BMECs and neural cells to
conduct CNS disease studies in vitro. Furthermore,
advances in the genetic manipulation of hPSCs using
tools such as bacterial artificial chromosomes [137], zinc
finger nucleases [138], and TAL effector nucleases [139]
could allow genetic manipulation akin to transgenic ani-
mal models to explore open-ended hypotheses regarding
cell-specific and genetic contributions to disease states.
While these strategies will likely always require an
in vivo complement to verify experimental outcomes,
they could substantially shorten exploratory endeavors
and translate outcomes observed in animal studies to
human cells. Given that hPSC culture techniques are be-
coming increasingly simplified with defined medium and
matrix components that do not require feeder cells [140]
and that the availability of hPSC lines is rapidly expand-
ing via nonprofit centers such as the American Type
Culture Collection (ATCC), the WISC Bank at the
WiCell Research Institute, and the Harvard Stem Cell
Institute, it should be possible for researchers to readily
apply these techniques in future BBB studies.Statement of institutional approval
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